Cytarabine

SKU: orb1309161

Description

Cytarabine (Ara-C) is a nucleoside analog DNA synthesis inhibitor with an IC50 of 16 nM. It functions by inhibiting DNA polymerase, leading to cell cycle arrest, autophagy, and apoptosis. This compound is widely used in cancer research, demonstrating antitumor activity in both in vitro and in vivo experimental models.

Research Area

Cell Biology, Infectious Disease & Virology, Metabolism Research, Molecular Biology

Key Properties

• CAS Number: 147-94-4
• MW: 243.22
• Purity: 99.92%
• Formula: C₉H₁₃N₃O₅
• SMILES: O[C@@H]1[C@@H](O[C@H](CO)[C@H]1O)N2C(=O)N=C(N)C=C2
• Target: Autophagy,Virus Protease,Endogenous Metabolite,DNA/RNA Synthesis,HSV,Apoptosis,Nucleoside Antimetabolite/Analog
• Solubility: H2O:24.3 mg/mL (99.91 mM);DMSO:262.5 mg/mL (1079.27 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:5 mg/mL (20.56 mM)

Bioactivity

• Target IC50:
  DNA synthesis:16 nM|CCRF-CEM cells proliferation:16 nM|L1210 cells proliferation:6.5 μM
• In Vivo:
  METHODS: To study chemotherapy resistance in AML, Cytarabine (10-60 mg/kg) was administered intraperitoneally to NSG mice bearing human AML tumors once daily for five days. RESULTS: In all mice treated with 60 mg/kg Cytarabine, cytoreduction occurred at 2 weeks post-treatment and relapsed 4-13 weeks post-treatment. There was a dose-response relationship in the model in terms of minimum leukemia burden and time to peripheral blood relapse. METHODS: To assay antitumor activity in vivo, Cytarabine (6.25 mg/kg once daily) and sorafenib (60 mg/kg twice daily) were administered intraperitoneally to a NOD-SCID-IL2R γnull mouse model harboring the human AML tumor U937 once weekly or for forty-eight days. RESULTS: Cytarabine in combination with sorafenib produced potent anti-AML activity in vivo. Translated with DeepL.com (free version)
• In Vitro:
  METHODS: Primary AML cells were treated with Cytarabine (10-5000 nM) for 24 h. Cell viability was measured using MTT method. RESULTS: Cytarabine showed a dose-dependent growth inhibitory effect with an IC50 of 1.12 μM. METHODS: Human histiocytic lymphoma cells U937 were treated with Cytarabine (10-1000 nM) for 72 h, and the cell cycle was detected by Flow Cytometry. RESULTS: Cytarabine dose-dependently decreased the proportion of cells in G1 phase and increased the proportion of cells in S phase in cells treated with 10 and 100 nM. At the highest dose of 1000 nM, Cytarabine caused a significant increase in the proportion of sub-G1 and G2/M phases. Translated with DeepL.com (free version)
• Cell Research:
  Cells are incubated in the presence of different concentrations of Cytarabine at 37 °C for 24, 48, and 72 hours. At the time of 20-, 44-, or 68-hour incubation in the presence of Cytarabine, 10 mL of cell proliferation reagent WST-1 solution is added. After 2- and 4-hour incubation with WST-1, cell metabolic activity is assessed with colorimetric changes quantified by measuring the absorbance in a spectrophotometer at 450 nm. And cell division times are calculated from eosin counting in parallel with viability assay(Only for Reference)

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

inhibit, Nucleoside Antimetabolite, Nucleoside Antimetabolite/Analog, NucleosideAntimetabolite, Inhibitor, Herpes simplex virus, HSV, Endogenous Metabolite, EndogenousMetabolite, Apoptosis, Analog, Arabinocytidine, Ara-C, Autophagy, Cytosine beta-D-arabinofuranoside, Cytosine Arabinoside, Cytosine b-D-arabinofuranoside, Cytosine β-D-arabinofuranoside, Cytarabine, DNA/RNA Synthesis, DNA synthesis, DNA Synthesis, DNASynthesis, RNA Synthesis, RNASynthesis, Orthopoxvirus

Compound Identifiers

PubChem CID

6253